Safety and efficacy of ezogabine (retigabine) in adults with refractory partial-onset seizures: Interim results from two ongoing open-label studies

A retrospective evaluation of retigabine in patients with cognitive impairment with highly drug-resistant epilepsy

“…The predominance of CNS-related adverse effects is in line with earlier work [5,6]. We saw only one case of genitourinary system side effects.…”

“…Whereas the efficacy of RTG is sufficiently proven in general populations with epilepsy through regulatory studies [2][3][4] and an open-label extension study [5], information regarding its use in everyday clinical practice and all the more in patients with cognitive impairments and Sy: symptomatic, cry: cryptogenic, CF: complex focal, GTCS: generalized tonic-clonic seizures, ID: intellectual disability, and cont./discont. : continued/discontinued after the red-hand letter.…”

Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a long-term open-label extension trial of up to 8 years

“…Lacosamide was well tolerated during this 8-year OLE trial, with 12.7% of patients discontinuing because of TEAEs, which lies within the range observed for other OLE studies of AEDs between 1 and 8 years of duration [9,10,[16][17][18][19][20][21][22][23]. Overall, the types of SAEs and TEAEs leading to discontinuation during this trial were similar to those observed in the other lacosamide OLE trials, as well as in pivotal double-blind placebo-controlled lacosamide trials [5,7,8], suggesting that long-term treatment with lacosamide was not associated with a different safety profile from that established in the pivotal trials.…”

Highights in the History of Epilepsy: The Last 200 Years

“…Two large-scale, phase III clinical trials have been conducted for retigabine. In both studies, AEs leading to discontinuation included dizziness, somnolence, headache, and fatigue [133–136]. …”